Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudia Benedict

Cardiovascular Disease Westminster, CO Medical Doctor

NPI 1407852411 CMS profile 109496

8300 Alcott St, Suite 300, Westminster, CO 80031

Open in the dashboard

General payments

$7,304

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claudia Benedict of Westminster, CO is reported in the CMS Open Payments database as having received $7,304 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,471 12
2024 General $1,209 52
2023 General $1,131 41
2022 General $996 46
2021 General $945 42
2020 General $729 37
2019 General $822 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudia Benedict
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Claudia Benedict were reported at $1,471. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Claudia Benedict Cardiovascular Disease median Middle half National median
2019 $822 $450 $127–$1,392 $163
2020 $729 $242 $77–$751 $114
2021 $945 $335 $101–$1,037 $132
2022 $996 $395 $121–$1,211 $149
2023 $1,131 $443 $136–$1,283 $160
2024 $1,209 $450 $136–$1,323 $164
2025 $1,471 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,604 15 payments
  2. Amgen Inc. $732 37 payments
  3. Pfizer Inc. $557 30 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $444 22 payments
  5. Janssen Pharmaceuticals, Inc $435 21 payments
  6. E.R. Squibb & Sons, L.L.C. $409 15 payments
  7. Abbott Laboratories $353 4 payments
  8. Novartis Pharmaceuticals Corporation $290 15 payments
  9. Sanofi-Aventis U.S. LLC $275 17 payments
  10. AstraZeneca Pharmaceuticals LP $222 14 payments
  11. Other $1,983 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,509 279 payments
  2. Travel and Lodging $788 2 payments
  3. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $1,391 10 payments
  2. Repatha $732 37 payments
  3. XARELTO $435 21 payments
  4. ELIQUIS $415 22 payments
  5. JARDIANCE $322 16 payments
  6. VERQUVO $263 14 payments
  7. VYNDAQEL $256 14 payments
  8. PAXLOVID $247 12 payments
  9. OPTIMIZER Cardiovascular Device $205 2 payments
  10. OPTIMIZER Cardiovascular Device $205 2 payments
  11. Other $3,808 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

3,646

Median for Cardiology: 2,533

Drug cost

$906,995

Median for Cardiology: $485,213

Branded share of claims

27.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 489 $539,278
Xarelto Rivaroxaban Brand 89 $119,522
Entresto Sacubitril/Valsartan Brand 86 $95,145
Repatha Sureclick Evolocumab Brand 67 $68,124
Jardiance Empagliflozin Brand 36 $47,243
Praluent Pen Alirocumab Brand 13 $6,594
Metoprolol Succinate Generic 279 $3,650
Losartan Potassium Generic 252 $2,226
Atorvastatin Calcium Generic 247 $2,138
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 52 $1,872

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$110,964

Of which drugs: $731

Medicare patients

778

Average age 75

Services billed

2,309

431 women, 347 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 48%
Arthritis 48%
Atrial fibrillation 38%
Chronic kidney disease 37%
Heart failure 33%
Diabetes 27%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 31 124 $623

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $138
$138 67 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $100
$100 36 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $94
$94 — —
ELIQUIS
  • PFIZER INC. $77
$77 489 —
VERQUVO
  • Merck Sharp & Dohme Corporation $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record